Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Lasmotinib · PHI-101

Small molecule · Inhibitor of CHK2 (CHEK2)

Phase 1 Most advanced trial (none active)

2 Registered trials

What is Lasmotinib?

Lasmotinib is an orally bioavailable inhibitor of checkpoint kinase 2 (CHK2). It binds to and inhibits CHK2 activity, preventing DNA damage repair and promoting tumor cell apoptosis. It is studied in platinum-resistant ovarian cancer, fallopian tube carcinoma, primary peritoneal carcinoma, and relapsed or refractory acute myeloid leukemia.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: PHI-101
Drug type: Small molecule
Targets: CHK2 (CHEK2)
Mechanism: Inhibitor of CHK2 (CHEK2)
Pathways: DNA damage response, apoptosis
Therapy area: Oncology
In trials of: IBIO
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 1
UNII: U2UY9TBQ8Z

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT04678102	Phase 1	Platinum-resistant Ovarian Cancer	Unknown	IBIO
NCT04842370	Phase 1	Relapsed or Refractory Acute Myeloid Leukemia	Unknown	IBIO

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Platinum-refractory Ovarian CarcinomaPlatinum-Resistant Fallopian Tube CarcinomaPlatinum-resistant Ovarian CancerPlatinum-Resistant Primary Peritoneal CarcinomaRelapsed or Refractory Acute Myeloid Leukemia

Sources

Updated Oct 3, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z